Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Patients With Peanut Allergy
NCT04984876Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of ligelizumab in peanut allergy, sponsored by Novartis. Started Dec 2021; status: terminated.
02
Drugs
ligelizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04984876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984876.